Brexit: No-deal dossier shows worst-case scenario - Gove
Read more at:
Showing posts with label medicine. Show all posts
Showing posts with label medicine. Show all posts
8/18/19
Britain - Brexit: No deal shows food and medicine shortages and unstable situation
6/23/17
Brexit: EU prepares to move two agencies from London - Laurence Pete
EU leaders have officially launched
the competition between member states to decide which will host two
London-based EU agencies, responsible for medicines and banking.
.
Some countries are bidding to host both the European Medicines Agency (EMA) and European Banking Authority (EBA).
It means hundreds of jobs moving from London, along with significant revenue from hotel stays and conferences.
Read more: EU prepares to move two agencies from London - BBC News
8/5/15
Drugs and Medicine Costs: Doctors Say Cancer Drug Prices Unaffordable by Diane Archer
Last month, in an article for Mayo Clinic Proceedings,
a group of 118 distinguished doctors united to question the pricing of
cancer drugs, which is "unsustainable," and to call for a new pricing
method. As this 60 Minutes report reveals,
the drug companies set the price of cancer drugs as high as they can.
And because of their market power, cancer drug prices have risen an
average of $8,500 a year for the last 15 years, a five to ten-fold
increase in the price of new cancer drugs over that period.
One in three Americans will have some form of cancer. And, even with insurance, they typically will end up bearing 20 to 30 percent of the cost of their cancer drugs. Insurers have no ability to rein in prices so insurers simply shift more drug costs to their members. People who need a new cancer drug easily could end up with out-of-pocket annual costs of $30,000 just for their cancer medication. Worse still, they might have to forego needed treatment. In 2014, the least expensive new cancer drug approved cost more than $120,000 a year.
American households have an average gross income of $52,000. And half of people over 65 have incomes under $23,500. Most Americans will need to sell assets or take out loans to pay for the drugs.
Not surprisingly, as many as one in five cancer patients today are not taking their cancer treatments or taking less than the amount they need. They and their families are suffering and some are needlessly dying. The doctors argue that something has to change.
The doctors offer several possible solutions, including Medicare drug price negotiation, which is the top policy priority for Americans. They also suggest legislation that would prevent pharmaceutical companies from paying generic drug companies to delay putting generic drugs in the market at lower prices and/or that would allow Americans to import drugs from abroad at lower prices. Click here to read their other proposed solutions.
Read more: Doctors Say Cancer Drug Prices Unaffordable | Diane Archer
One in three Americans will have some form of cancer. And, even with insurance, they typically will end up bearing 20 to 30 percent of the cost of their cancer drugs. Insurers have no ability to rein in prices so insurers simply shift more drug costs to their members. People who need a new cancer drug easily could end up with out-of-pocket annual costs of $30,000 just for their cancer medication. Worse still, they might have to forego needed treatment. In 2014, the least expensive new cancer drug approved cost more than $120,000 a year.
American households have an average gross income of $52,000. And half of people over 65 have incomes under $23,500. Most Americans will need to sell assets or take out loans to pay for the drugs.
Not surprisingly, as many as one in five cancer patients today are not taking their cancer treatments or taking less than the amount they need. They and their families are suffering and some are needlessly dying. The doctors argue that something has to change.
The doctors offer several possible solutions, including Medicare drug price negotiation, which is the top policy priority for Americans. They also suggest legislation that would prevent pharmaceutical companies from paying generic drug companies to delay putting generic drugs in the market at lower prices and/or that would allow Americans to import drugs from abroad at lower prices. Click here to read their other proposed solutions.
Read more: Doctors Say Cancer Drug Prices Unaffordable | Diane Archer
4/21/14
Pharmaceutical Industry: Do free samples influence the way doctors prescribe drugs?
A new study from Stanford University's School of Medicine found that
doctors who are allowed to hand out free samples of expensive drugs
prescribe those drugs more often than doctors who don’t have access to
free samples. Dr. Alfred Lane, senior author of the report, talks with
Hari Sreenivasan about the implications of the findings.
See more: Video: Do free samples influence the way doctors prescribe drugs? | Watch PBS NewsHour Online | PBS Video
See more: Video: Do free samples influence the way doctors prescribe drugs? | Watch PBS NewsHour Online | PBS Video
10/15/13
Medicine: Tiny, wireless pacemaker due to be launched in Europe
A miniaturized, wireless pacemaker that can be inserted into the body without invasive surgery has been given approval for use in the European Union.
It is less than 10% of the size of a conventional pacemaker and uses a built-in battery.
Experts said it was an "exciting development" but at a very early stage.
The pacemaker has yet to receive full US Food and Drug Administration (FDA) approval.
Conventional pacemakers require a patient to be cut open and a pocket created in the body to house the pacemaker and associated wires.
Such wires are regarded as the component of pacemakers most likely to fail. The pocket created for the pacemaker is also liable to infection.
By contrast the Nanostim pacemaker is delivered via a catheter inserted through the femoral vein near the groin.
Read more: Nanostim pacemaker
3/4/13
AIDS: French scientists urge caution over HIV 'cure' - by Charlotte Boitiaux
US scientists say they have cured a baby born with HIV for the first time, in a case that could lead to significant advancements in treatment for infected children. But the two leading HIV specialists in France are urging caution.
It’s an incredible story, and totally unique,” French doctor and journalist Jean-Daniel Flaysakier wrote on his medical blog on Sunday.
However, the considerable enthusiasm generated by the news is not fully shared by all AIDS specialists.
Professor Luc Montagnier, widely credited for discovering the AIDS virus, has called for “caution,” for two main reasons. One is that the medical profile of the child concerned is rare. “Only one third of babies born from HIV-positive mothers who have not been treated are infected by the virus,” he told FRANCE 24. “70% are healthy at birth.”
Furthermore, there is no guarantee that the virus -- currently dormant but not fully destroyed by the immune system or the treatments -- will not be reactivated at any given moment.
Read more: French scientists urge caution over HIV 'cure' - HEALTH - FRANCE 24
It’s an incredible story, and totally unique,” French doctor and journalist Jean-Daniel Flaysakier wrote on his medical blog on Sunday.
However, the considerable enthusiasm generated by the news is not fully shared by all AIDS specialists.
Professor Luc Montagnier, widely credited for discovering the AIDS virus, has called for “caution,” for two main reasons. One is that the medical profile of the child concerned is rare. “Only one third of babies born from HIV-positive mothers who have not been treated are infected by the virus,” he told FRANCE 24. “70% are healthy at birth.”
Furthermore, there is no guarantee that the virus -- currently dormant but not fully destroyed by the immune system or the treatments -- will not be reactivated at any given moment.
Read more: French scientists urge caution over HIV 'cure' - HEALTH - FRANCE 24
7/14/07
Forbes.com: Bayer says oral contraceptive YAZ receives approval in the Netherlands - drug also clears acne
For the complete report from Forbes.com click on this link
Bayer says oral contraceptive YAZ receives approval in the Netherlands - drug also clears acne
Bayer AG said its low-dose oral contraceptive YAZ received regulatory approval in the Netherlands, both for preventing unwanted pregnancies and treating acne. This regulatory nod -- the first in Europe -- will serve as a reference in the EU mutual recognition procedure that Bayer plans to launch in order to gain Europe-wide marketing approval.
YAZ has been on the US market since April 2006 and posts the highest growth rate among brand-name contraceptives.
Subscribe to:
Posts (Atom)